Summary of siRNA Drug Industry Conference Call Industry Overview - The siRNA drug industry is gaining traction as a prominent direction in new drug development due to its ability to precisely silence pathogenic proteins, offering high degradation efficiency and prolonged action time compared to traditional small molecules and biologics [1][1] - The core technology in siRNA drugs is delivery, with a focus on extrahepatic delivery as the current breakthrough area. Various delivery methods include LNP, antibodies, peptides, and VLP, each with its advantages and disadvantages, with AOC showing slightly faster development [1][1] Key Insights - Major international players in the siRNA industry, such as Alnylam, have reached a harvest period with their GalNAc liver delivery system, which is recognized for its high delivery efficiency, strong specificity, and lasting effects. Other companies like Arrowhead and Dicerna are advancing in clinical stages or commercialization targeting cardiovascular common targets like PCSK9, AGT, Lp(a), and ApoC3 [1][1] - Research on extrahepatic organs such as muscles, the nervous system, and eyes is still in early development stages. Alnylam's C16 delivery platform has shown potential in the CNS field, while Arrowhead's TRiM platform has shown promise in adipose tissue, indicating that the discovery of new targets and extrahepatic delivery platforms will be core competitive points in the future [1][1] Domestic Market Dynamics - The domestic siRNA drug development landscape is characterized by a diverse array of startups, with Big Pharma also entering the market. Domestic companies have become significant players in the global siRNA arena, especially as many chronic disease drugs approach the end of their sales lifecycle, necessitating new technological iterations [2][2] - There is a strong business development willingness among multinational corporations (MNCs) in the liver delivery sector, with collaborations established between companies such as 舶望 and Novartis, 圣因 and Roche, 瑞博 and Madrigal, and 前沿 and GSK [2][2] - Domestic enterprises are actively pursuing dual-target and extrahepatic delivery strategies, gradually narrowing the gap with overseas competitors and potentially leading the industry development direction in the future [2][2] Investment Recommendations - Recommended stocks to watch include: - A-shares: 恒瑞医药, 必贝特, 前沿生物, 悦康药业, 阳光诺和, 福元医药 - Hong Kong stocks: 瑞博生物, 石药集团, 中国生物制药, 靖因药业 (already filed for listing) [3][3] - Risk factors to consider include: 1. Clinical progress of innovative drugs not meeting expectations 2. Clinical data of innovative drugs not meeting expectations 3. Sales performance of innovative drugs post-launch not meeting expectations 4. Geopolitical risks [3][3]

Group 1 - The core advantage of siRNA drugs lies in their ability to precisely silence pathogenic proteins, with delivery systems being the key technology [1] - siRNA therapies are gaining popularity in new drug development due to their high efficiency in degrading proteins and prolonged action time compared to traditional small molecules and biologics [1] - The focus of technological breakthroughs is on extrahepatic delivery, with various delivery methods such as LNP, antibodies, peptides, and VLP, each having its own advantages and disadvantages [1] Group 2 - Overseas giants like Alnylam have entered a harvest phase with their GalNAc liver delivery platform, which is recognized for its high efficiency and specificity [2] - Other companies such as Arrowhead and Dicerna are advancing siRNA drugs targeting common cardiovascular markers and are in late-stage clinical or commercial phases [2] - Research on extrahepatic delivery for muscle, nervous system, and ocular targets is still in early development, with potential seen in Alnylam's C16 platform and Arrowhead's TRiM platform [2] Group 3 - Domestic siRNA drug development is flourishing, with a variety of directions from startups and major pharmaceutical companies entering the field [3] - Collaborations between domestic companies and multinational corporations (MNCs) are increasing, with notable partnerships established with Novartis, Roche, and GSK [3] - Domestic firms are actively pursuing dual-target and extrahepatic delivery strategies, narrowing the gap with overseas competitors and potentially leading industry development [3]

Summary of siRNA Industry Insights Industry Overview - The siRNA drug market is projected to reach $50.3 billion by 2040, indicating a significant growth opportunity in the nucleic acid therapy sector, which is gaining traction as a new drug development direction [1][1][1] Key Insights - siRNA drugs offer high efficiency, low toxicity, and long-lasting effects compared to traditional small molecules and biologics, making them a popular choice in new drug development [1][1][1] - The GalNAc liver delivery platform has matured, showing high delivery efficiency and specificity, becoming the standard for liver-targeted siRNA drugs. Notable targets include PCSK9, AGT, Lp(a), and ApoC3, which have demonstrated therapeutic potential [1][1][1] - There is potential for breakthroughs in extrahepatic delivery systems, with early-stage developments in areas such as muscle, CNS, and ocular applications. Alnylam's C16 delivery platform is showing promise in Alzheimer's disease, while Arrowhead and Wave Life Sciences are exploring fat tissue targets [1][1][1] Market Dynamics - Domestic siRNA companies are positioned to capitalize on the demand for new technologies as traditional chronic disease drugs approach the end of their sales lifecycle. Collaborations with multinational corporations (MNCs) are expected to increase, particularly in liver delivery systems [2][2][2] - The industry outlook is optimistic, with domestic siRNA drugs likely to secure partnerships in popular targets like PCSK9 and Lp(a). New demands in weight loss and CNS delivery are further opening up the market as international giants make breakthroughs [2][2][2] Relevant Companies - A-share listed companies: Yuyuan Pharmaceutical, Frontier Biotech, Fuyuan Pharmaceutical, Bibetech, Sunshine Nuohuo, Chengdu Xian Dao - Hong Kong listed companies: Reebio, and upcoming IPOs such as Jingyin Biotech and Bowe Pharmaceutical - Upstream industry chain participants include WuXi AppTec, Lianhua Technology, Aorite, Lanxiao Technology, Nawei Microbiology, and Jiuzhou Pharmaceutical [2][2][2]